Q3 2023 Sumitomo Pharma Co Ltd Earnings Call Transcript
My name is Hisayoshi Kashima. Based on the presentation material, I will report on the third quarter results for FY 2022 and the current status of clinical development. Please refer to Page 3. I would like to report on our financial results on a core basis for the third quarter, the accounting standard is IFRS.
Revenue was JPY 460.3 billion, an increase of JPY 28.2 billion from the same period last year. Although revenue in Japan segment declined due to the NHI drug price revision and other factors, revenue in the North America, China and other regions segments increased due to the impact of foreign currency translation and sales growth of Sumitovant Group products. In addition to the increase in gross profit due to higher revenues, we recorded other operating profit and expenses such as gains on the sales of a priority with the voucher and the divestiture of marketing rights for BROVANA and XOPENEX HFA. On the other hand, core operating profit decreased by JPY 16 billion year-on-year to JPY 42.9 billion due to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
